IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

Rhea-AI Summary

IDEAYA Biosciences (Nasdaq: IDYA) will present complete Phase 2/3 registrational data from the OptimUM-02 trial of darovasertib plus crizotinib in 1L HLA*A2-negative metastatic uveal melanoma at ASCO 2026.

The late-breaking oral presentation (LBA9503) is scheduled for June 1, 2026, 8-11AM CDT in the Melanoma/Skin Cancers session; Dr. Marlana Orloff will present additional data not included in prior topline disclosure.

News Market Reaction – IDYA

-5.27%

20 alerts

-5.27% Session close to close

-2.6% Trough in 2 hr 59 min

$2.82B Market Cap

0.4x Rel. Volume

In the Apr 21 session, IDYA declined 5.27%, reflecting a notable negative market reaction. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.3% in the session following this news. A negative reaction despite the ASCO late‑...

Analysis

The stock moved -5.3% in the session following this news. A negative reaction despite the ASCO late‑breaking slot would contrast with prior OptimUM‑02 topline data, which saw a 7.61% gain. Such weakness could mirror the earlier divergence seen on a Phase 1 FPI update and might reflect profit‑taking or heightened expectations for the detailed dataset, rather than a clear shift in the underlying registrational story.

Key Figures

ASCO 2026 dates: May 29–June 2, 2026 Presentation date: June 1, 2026 Presentation time: 8–11 AM CDT +3 more

6 metrics

ASCO 2026 dates May 29–June 2, 2026 American Society of Clinical Oncology Annual Meeting schedule

Presentation date June 1, 2026 OptimUM-02 oral late-breaking abstract session

Presentation time 8–11 AM CDT ASCO Melanoma/Skin Cancers Oral Abstract Session

Late-breaking abstract ID LBA9503 ASCO late-breaking abstract number for OptimUM-02

Trial phase Phase 2/3 Registrational OptimUM-02 trial of darovasertib plus crizotinib

Treatment line First-line (1L) HLA*A2-negative metastatic uveal melanoma setting

Previous Clinical trial Reports

5 past events · Latest: Apr 13 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 13	Registrational topline data	Positive	+7.6%	Positive Phase 2/3 OptimUM-02 topline results for darovasertib plus crizotinib.
Apr 06	Phase 1 trial start	Positive	-1.2%	First-patient-in for Phase 1 trial of IDE574 dual KAT6/7 inhibitor.
Mar 30	Phase 1 combo start	Positive	+3.3%	First-patient-in for IDE849 plus IDE161 combination in DLL3-upregulated tumors.
Mar 09	Phase 1 trial start	Positive	+5.7%	First-patient-in for IDE892 PRMT5 inhibitor trial in MTAP-deleted tumors.
Feb 27	Milestone trial dosing	Positive	+2.6%	First patient dosed in Phase 1 trial of IDE034 B7H3/PTK7 bispecific ADC.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial updates for IDEAYA have generally drawn positive price reactions, with four of the last five tagged clinical events showing gains, including the prior OptimUM-02 topline data.

Recent Company History

Over recent months, IDEAYA has steadily advanced a broad clinical pipeline. Key events included positive topline Phase 2/3 OptimUM-02 data for darovasertib plus crizotinib in metastatic uveal melanoma on Apr 13, 2026, which saw a 7.61% gain. Multiple first‑patient‑in milestones were reported across IDE574, IDE849/IDE161, IDE892, and IDE034 programs, with mostly positive single‑day reactions. Today’s ASCO late‑breaking oral presentation announcement follows the prior topline release, positioning OptimUM‑02 for a detailed data unveiling at a major oncology meeting.

Key Terms

late-breaking abstract, phase 2/3, registrational trial, hla*a2-negative, +2 more

6 terms

late-breaking abstract regulatory

"announced they have been selected for a late-breaking abstract (LBA) oral presentation"

A late-breaking abstract is a short summary of new clinical or scientific data submitted and accepted for presentation at a medical or scientific conference after the usual submission deadline. Investors watch these because they often contain fresh, potentially market-moving results—like seeing the final score of a game released just before kickoff—so they can change expectations about a drug’s safety, effectiveness, or commercial prospects.

phase 2/3 medical

"complete data from the Phase 2/3 registrational trial (OptimUM-02) of darovasertib"

A phase 2/3 trial is a combined clinical study that first evaluates how well a treatment works and the best dose, then expands into a larger test to confirm those results and safety. For investors, it matters because moving into a phase 2/3 signals that an experimental therapy has shown initial promise and will be tested at scale, which can materially change the odds and timeline for regulatory approval and commercial potential.

registrational trial regulatory

"complete data from the Phase 2/3 registrational trial (OptimUM-02) of darovasertib"

A registrational trial is the large, definitive clinical study designed to provide the evidence regulators need to decide whether a new drug or medical product can be approved for sale. Think of it as the final exam for a treatment: passing it can unlock widespread market access and potential revenues, while failing it can sharply reduce a product’s commercial prospects and raise investment risk.

hla*a2-negative medical

"darovasertib in combination with crizotinib in first-line (1L) HLA*A2-negative metastatic"

HLA-A2-negative means an individual does not carry the HLA-A2 version of a common immune-system gene. HLA types act like locks on cells that determine which immune-targeted therapies and vaccines can engage a patient’s immune system, so being HLA-A2-negative can make a person ineligible for treatments or clinical trials designed for HLA-A2 carriers, which affects the potential patient pool and commercial market for those therapies.

metastatic uveal melanoma medical

"first-line (1L) HLA*A2-negative metastatic uveal melanoma at the 2026 American"

Metastatic uveal melanoma is an eye cancer that begins in the uvea (the eye’s middle layer) and has spread to other parts of the body, most often the liver. For investors, it matters because the spread makes the disease much harder to treat, so clinical trial results, regulatory approvals, and new therapies can dramatically change a drug developer’s prospects—think of a small house fire that spreads to the whole neighborhood, changing the value of nearby properties.

oral abstract session technical

"Date and Time: June 1, 2026, 8-11AM CDT, Oral Abstract Session, Melanoma/Skin"

An oral abstract session is a scheduled conference presentation where researchers speak live about a summarized study or result selected from submitted abstracts, typically followed by expert questions. For investors it serves like an early product demo or progress update — providing timely insight into scientific or clinical progress, peer reaction, and potential regulatory or commercial implications that can influence a company’s prospects and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking abstract (LBA) oral presentation to provide the complete data from the Phase 2/3 registrational trial (OptimUM-02) of darovasertib in combination with crizotinib in first-line (1L) HLA*A2-negative metastatic uveal melanoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 29-June 2 in Chicago, Illinois. The presentation will include detail and additional data from OptimUM-02 that were not disclosed with the company's topline release.

Presentation details

Late-Breaking Abstract Number: LBA9503

Date and Time: June 1, 2026, 8-11AM CDT, Oral Abstract Session, Melanoma/Skin Cancers

Title: Darovasertib Plus Crizotinib vs Investigator's Choice as First-Line Treatment for Patients with HLA-A2 Negative Metastatic Uveal Melanoma: Primary Results from the OptimUM-02 trial

Presenter: Dr. Marlana Orloff, M.D., Associate Professor of Medical Oncology, Thomas Jefferson University Hospital

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding IDEAYA Biosciences' expectations with respect to the presentation of data from the Phase 2/3 OptimUM-02 trial, including the scope, content, timing, and potential significance of additional data to be presented at the 2026 ASCO Annual Meeting, as well as the potential therapeutic benefit and clinical development of darovasertib in combination with crizotinib for the treatment of metastatic uveal melanoma.  Such forward-looking statements are based on management's current expectations, assumptions and beliefs and involve substantial risks and uncertainties that could cause actual results, including, but not limited to, those related to IDEAYA's clinical programs, commercial activities, and performance and/or achievements, to differ significantly and/or materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the process of designing and conducting preclinical and clinical trials,  enrollment rates, safety outcomes, efficacy results, regulatory interactions and decisions, and the ability to translate preclinical findings into clinical benefit, manufacturing and supply risks, competition, changes in standard of care, the timing and success of commercialization efforts, the outcome of collaborations and licensing arrangements,  IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of financial resources to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements.  A further description of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, are in IDEAYA's filings with the Securities and Exchange Commission, including IDEAYA's most recent Annual Report on Form 10-K and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact

IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer  
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-late-breaking-abstract-oral-presentation-at-asco-2026-to-provide-complete-data-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-1l-hlaa2-negative-meta-302747826.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

When will IDEAYA (IDYA) present OptimUM-02 data at ASCO 2026?

IDEAYA will present OptimUM-02 data on June 1, 2026, 8-11AM CDT as a late-breaking oral abstract. According to IDEAYA, the session (LBA9503) is in the Melanoma/Skin Cancers oral abstract session at ASCO 2026 in Chicago.

What will IDEAYA (IDYA) reveal about darovasertib plus crizotinib at ASCO?

IDEAYA will provide the complete Phase 2/3 registrational trial data from OptimUM-02, including additional details beyond topline results. According to IDEAYA, the presentation will cover primary results and previously undisclosed data points.

Who is presenting IDEAYA's OptimUM-02 late-breaking abstract at ASCO 2026?

Dr. Marlana Orloff will deliver the oral presentation for IDEAYA on June 1, 2026. According to IDEAYA, Dr. Orloff is associate professor of medical oncology at Thomas Jefferson University Hospital and will present the OptimUM-02 primary results.

What is the Late-Breaking Abstract number for IDEAYA's ASCO presentation (IDYA)?

The late-breaking abstract number is LBA9503 for IDEAYA's ASCO presentation on OptimUM-02. According to IDEAYA, LBA9503 corresponds to the oral abstract session covering melanoma and skin cancers on June 1, 2026.

Will IDEAYA's ASCO presentation include new OptimUM-02 results beyond topline data?

Yes—IDEAYA says the oral presentation will include additional OptimUM-02 data not disclosed with topline results. According to IDEAYA, attendees will receive more detailed efficacy and/or safety readouts from the registrational trial.

How can investors follow IDEAYA's (IDYA) OptimUM-02 presentation at ASCO 2026?

Investors can attend the ASCO session in Chicago or follow institutional coverage and company updates after the presentation. According to IDEAYA, the oral session is scheduled June 1, 2026, and the company typically issues follow-up materials after ASCO presentations.